The 2026 Cadillac Vistiq is getting its second price adjustment since the all-electric three-row crossover made its debut late in 2024. According to the latest pricing information, the 2026 Vistiq ...

The 2026 Cadillac CT5 carries over mostly unchanged from the refreshed 2025 model year, once again cradling internal combustion power up front and oodles of luxury in the cabin. It’s a nice ...

In 2026, Cadillac has built up a reputation for being able to perfectly execute the careful blending of luxury and tire-melting performance in one graciously styled package, as illustrated by the 2026 ...

Kyle has written professionally across the motorsport and motoring world since graduating from Plymouth University in 2018, and has acted as the MotoGP editor for Motorsport Week and as a Features ...

Cadillac will ask you to pay almost $27,000 to upgrade your CT5-V Blackwing sedan. It brings bucket seats, blue brake calipers, and Deep Ocean blue paint, but it is just show and no go. The upgrade ...

The Cadillac CT5-V Blackwing is arguably the best perfomance-focused sedan that money can buy. With a 668-hp supercharged V-8 and an available six-speed manual, the 2026 model's $102,795 starting ...

General Motors quietly re-entered Australia with a lot riding on a single car following the death of Holden. It didn’t deliver a ute, muscle car or affordable hatchback, but instead pitched up a ...

The 2026 Cadillac CT5-V Blackwing is reportedly adding a limited-production Deep Ocean package that's pretty expensive. The kit costs $26,995 and will only be available on 200 total cars, according to ...

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title, registration ...

The 500 cubic-inch displacement engine in today's Nice Price or No Dice Eldorado is one of the largest V8s ever offered in a ...

BofA lowered the firm’s price target on Caribou Biosciences (CRBU) to $6 from $8 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its ...